Stock Analysis Report

Executive Summary

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases.

Snowflake Analysis

Excellent balance sheet with moderate growth potential.

Share Price & News

How has Cantargia's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: 7V3's share price has been volatile over the past 3 months.

Market Performance

7 Day Return




DE Biotechs


DE Market

1 Year Return




DE Biotechs


DE Market

Return vs Industry: 7V3 exceeded the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: 7V3 exceeded the German Market which returned 6.1% over the past year.

Shareholder returns

7 Day-13.7%-4.1%-5.7%
30 Day6.1%-8.2%-5.7%
90 Day37.7%-2.0%-3.6%
1 Year28.4%28.4%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Cantargia's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is Cantargia undervalued compared to its fair value and its price relative to the market?


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: 7V3 (€2.01) is trading above our estimate of fair value (€0.4)

Significantly Below Fair Value: 7V3 is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: 7V3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 7V3 is unprofitable, so we can't compare its PE Ratio to the German market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 7V3's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 7V3 is overvalued based on its PB Ratio (9.2x) compared to the DE Biotechs industry average (3.2x).

Next Steps

Future Growth

How is Cantargia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7V3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 7V3 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 7V3's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if 7V3's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 7V3's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 7V3's Return on Equity is forecast to be low in 3 years time (19.7%).

Next Steps

Past Performance

How has Cantargia performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 7V3 is currently unprofitable.

Growing Profit Margin: 7V3 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 7V3 is unprofitable, and losses have increased over the past 5 years at a rate of -41.2% per year.

Accelerating Growth: Unable to compare 7V3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7V3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).

Return on Equity

High ROE: 7V3 has a negative Return on Equity (-57.35%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Next Steps

Financial Health

How is Cantargia's financial position?

Financial Position Analysis

Short Term Liabilities: 7V3's short term assets (SEK213.8M) exceed its short term liabilities (SEK35.3M).

Long Term Liabilities: 7V3 has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: 7V3 is debt free.

Reducing Debt: 7V3 has not had any debt for past 5 years.

Balance Sheet

Inventory Level: 7V3 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 7V3's debt is covered by short term assets.

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 7V3 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 7V3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Next Steps


What is Cantargia's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market


Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 7V3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 7V3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7V3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7V3's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7V3's dividend in 3 years as they are not forecast to pay a notable one for the German market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Göran Forsberg (56yo)





Mr. Göran Forsberg has been the Chief Executive Officer at Cantargia AB since June 2014. Mr. Forsberg served as the Chief Business Officer of Active Biotech AB. He has more than 25 years' experience in bot ...

CEO Compensation Analysis

Compensation vs Market: Göran's total compensation ($USD321.81K) is below average for companies of similar size in the German market ($USD627.72K).

Compensation vs Earnings: Göran's compensation has increased whilst the company is unprofitable.

Leadership Team

Göran Forsberg
Chief Executive Officer5.7yrskr3.13m0.10% SEK198.8k
Marcus Järås
Founder & Scientific Advisor0yrsno datano data
Kjell Sjöström
0yrsno datano data
Bengt Jöndell
Chief Financial Officer2.8yrsno data0.089% SEK172.0k
Liselotte Larsson
Vice President of Operations6.1yrsno data0.028% SEK54.8k


Average Tenure


Average Age

Experienced Management: 7V3's management team is seasoned and experienced (5.7 years average tenure).

Board Members

Gunnar Magnus Severus Persson
Chairman of the Board4.1yrskr585.00k0.049% SEK95.5k
Claus Andersson
Independent Director7.1yrskr240.00kno data
Anders Martin-Löf
Independent Director1.8yrskr329.00k0.026% SEK50.9k
Thoas Fioretos
Founder & Director10.1yrskr256.00k0.53% SEK1.0m
Karin Leandersson
Independent Director4.1yrskr276.00kno data
Patricia Delaite
Independent Director2.3yrskr343.00kno data


Average Tenure


Average Age

Experienced Board: 7V3's board of directors are considered experienced (4.1 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: 7V3 insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.

Top Shareholders

Company Information

Cantargia AB (publ)'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Cantargia AB (publ)
  • Ticker: 7V3
  • Exchange: DB
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr2.043b
  • Listing Market Cap: kr193.209m
  • Shares outstanding: 91.01m
  • Website: https://www.cantargia.com

Number of Employees


  • Cantargia AB (publ)
  • Scheelevägen 2
  • Medicon Village
  • Lund
  • Skåne County
  • 223 81
  • Sweden


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CANTAOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMar 2015
7V3DB (Deutsche Boerse AG)YesShare CapitalDEEURMar 2015
CANTASBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKMar 2015


Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 23:33
End of Day Share Price2020/02/25 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.